DE602004023093D1 - N mit einem abgabemittel in mikronisierter form - Google Patents

N mit einem abgabemittel in mikronisierter form

Info

Publication number
DE602004023093D1
DE602004023093D1 DE602004023093T DE602004023093T DE602004023093D1 DE 602004023093 D1 DE602004023093 D1 DE 602004023093D1 DE 602004023093 T DE602004023093 T DE 602004023093T DE 602004023093 T DE602004023093 T DE 602004023093T DE 602004023093 D1 DE602004023093 D1 DE 602004023093D1
Authority
DE
Germany
Prior art keywords
pharmacologically active
agent
dispenser
delivery
micronized form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004023093T
Other languages
English (en)
Inventor
Shoufeng Li
Anasuya Ashok Ghosh
Simon David Bateman
Moise Azria
Alan Edward Royce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis Pharma GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH, Novartis AG filed Critical Novartis Pharma GmbH
Publication of DE602004023093D1 publication Critical patent/DE602004023093D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
DE602004023093T 2003-07-11 2004-07-09 N mit einem abgabemittel in mikronisierter form Active DE602004023093D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48649503P 2003-07-11 2003-07-11
PCT/EP2004/007584 WO2005004900A1 (en) 2003-07-11 2004-07-09 Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form

Publications (1)

Publication Number Publication Date
DE602004023093D1 true DE602004023093D1 (de) 2009-10-22

Family

ID=34062133

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004023093T Active DE602004023093D1 (de) 2003-07-11 2004-07-09 N mit einem abgabemittel in mikronisierter form

Country Status (15)

Country Link
US (3) US20070065505A1 (de)
EP (1) EP1651248B1 (de)
JP (1) JP5032844B2 (de)
CN (1) CN1809377B (de)
AT (1) ATE442158T1 (de)
AU (1) AU2004255458B2 (de)
BR (1) BRPI0412458A (de)
CA (1) CA2529604C (de)
DE (1) DE602004023093D1 (de)
ES (1) ES2330638T3 (de)
HK (1) HK1089950A1 (de)
MX (1) MXPA06000446A (de)
PL (1) PL1651248T3 (de)
PT (1) PT1651248E (de)
WO (1) WO2005004900A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL210258B1 (pl) * 2001-08-17 2011-12-30 Novartis Ag Kompozycja farmaceutyczna do podawania doustnego fragmentów hormonu przytarczyc oraz jej zastosowanie
JP2008509933A (ja) * 2004-08-13 2008-04-03 エミスフェアー・テクノロジーズ・インク 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
RU2507196C2 (ru) * 2005-09-19 2014-02-20 Эмисфире Текнолоджис, Инк. Кристаллические формы динатриевой соли n-(5-хлорсалицилоил)-8-аминокаприловой кислоты
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
JP5042312B2 (ja) * 2006-08-31 2012-10-03 ノバルティス アーゲー Ｈｇｈを含む経口送達用医薬組成物
AR062925A1 (es) * 2006-09-22 2008-12-17 Novartis Ag Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
DK2215047T3 (da) 2007-11-02 2014-02-03 Emisphere Tech Inc Fremgangsmåde til behandling af vitamin b12-mangel
CA2790708A1 (en) * 2010-02-24 2011-09-01 Emisphere Technologies, Inc. Oral b12 therapy
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
CN106117344B (zh) 2011-04-12 2020-11-03 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
HRP20231613T1 (hr) 2012-03-22 2024-03-15 Novo Nordisk A/S Pripravci koji sadrže sredstvo za unošenje i njihova priprava
EP2863895B1 (de) 2012-06-20 2021-04-14 Novo Nordisk A/S Tablettenformulierung enthaltend ein peptid und einen adsorptionsvermittler
CN104095828A (zh) * 2014-07-29 2014-10-15 中国药科大学 一种降钙素口服肠溶组合物及其制备方法
EP3746111B1 (de) 2018-02-02 2023-07-19 Novo Nordisk A/S Feste zusammensetzungen mit einem glp-1-agonisten, einem salz aus n-(8-(2-hydroxybenzoyl)amino)caprylsäure und einem schmierstoff
IL307875A (en) 2021-04-22 2023-12-01 Civi Biopharma Inc Oral administration of oligonucleotides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US6413546B1 (en) * 1999-03-18 2002-07-02 Indena, S.P.A. Tablets incorporating isoflavone plant extracts and methods of manufacturing them
ES2235854T3 (es) * 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
SK285128B6 (sk) * 1999-12-28 2006-07-07 Zentiva, A. S. Liečivý prípravok s riadeným uvoľňovaním obsahujúci tramadol hydrochlorid a spôsob jeho prípravy
US6544553B1 (en) * 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents

Also Published As

Publication number Publication date
JP2009513528A (ja) 2009-04-02
US20080234179A1 (en) 2008-09-25
EP1651248B1 (de) 2009-09-09
AU2004255458B2 (en) 2007-09-13
PL1651248T3 (pl) 2010-02-26
AU2004255458A1 (en) 2005-01-20
PT1651248E (pt) 2009-11-10
BRPI0412458A (pt) 2006-10-17
EP1651248A1 (de) 2006-05-03
US8435946B2 (en) 2013-05-07
ES2330638T3 (es) 2009-12-14
ATE442158T1 (de) 2009-09-15
US20130230593A1 (en) 2013-09-05
CA2529604C (en) 2012-05-08
US20070065505A1 (en) 2007-03-22
US8748383B2 (en) 2014-06-10
CN1809377B (zh) 2010-08-04
WO2005004900A1 (en) 2005-01-20
MXPA06000446A (es) 2006-04-07
HK1089950A1 (en) 2006-12-15
CN1809377A (zh) 2006-07-26
JP5032844B2 (ja) 2012-09-26
CA2529604A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
HK1089950A1 (en) Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
ATE513541T1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung von calcitonin
EA200501586A1 (ru) Фармацевтические продукты
ATE491439T1 (de) Pharmazeutische zusammensetzungen enthaltend einen opioidantagonisten
WO2008021088A3 (en) Salicylanilides enhance oral delivery of therapeutic peptides
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
MX2007005521A (es) Formulaciones estables de peptidos insulinotropicos.
CY1108547T1 (el) Αναλογα σωματοστατινης
CY1105648T1 (el) Filbanserin για την θεραπεια εξτραπυραμιδικων διαταραχων κινησης
ATE354362T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
DK1641820T3 (da) Fra RasGap afledt peptid til selektiv at dræbe kræftceller
ATE361743T1 (de) Beschichtete minitabletten von venlafaxinhydrochlorid mit verlängerter freisetzung
BRPI0412364A (pt) composição farmacêutica sólida, compreendendo amisulpride
EA200600953A1 (ru) Дозированные формы торсемида пролонгированного высвобождения
DE602006012962D1 (de) Pharmazeutische Zubereitungen von Ciprofloxacin
EA200501565A1 (ru) Предназначенная для перорального приёма лекарственная форма для антагонистов протонного насоса
ATE373488T1 (de) Antimykobakterielle pharmazeutische zusammensetzung mit einem arzneimittel gegen tuberkulose
HRP20070081T3 (en) Nasal pharmaceutical composition of piribedil
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
HUP0500270A2 (en) Pharmacologically active peptide derivatives, process for their preparation and pharmaceutical compositions containing the same
UY27122A1 (es) Una composición farmacéutica que comprende de 2 a 4 mg de 5-(a-(2-(n-metil-n-(2-piridil)amino)etoxi)bencil)tiazolidin-2,4-diona
ATE429905T1 (de) Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung
CY1115063T1 (el) Μεθοδος και συνθεση για τη θεραπεια φλεγμονωδων διαταραχων
SE0302782D0 (sv) Composition for sustained drug delivery

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS AG, BASEL, CH

8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN